Research on FDA Bioresearch Monitoring Inspection System and Its Enlightenment to China
ZANG Ke-cheng1,2,3, DU Yi1,2, SHAO Rong1,2*
Author information+
1. Institute of Regulatory Science, China Pharmaceutical University, Nanjing 211198, China; 2. NMPA Key Laboratory for Drug Regulatory Innovation and Evaluation, Nanjing 211198, China; 3. Center for Food and Drug Inspection of NMPA, Beijing 100044, China
OBJECTIVE To study the FDA bioresearch monitoring inspection system and the problems in China's drug research inspections. METHODS This article studied the laws and regulations, guideline basis, inspection procedures, inspection types, inspection points and common inspection defects. First, we searched the regulatory guidelines and research literature of the bioresearch monitoring inspection system, then we collected the fiscal year work status reports of the bioresearch monitoring inspection system published on the FDA website. RESULTS The bioresearch monitoring inspection system has a complete set of guidelines as a guide, a specialized team of inspectors to perform inspections, and an internal information platform, eNSpect, to assist inspectors in their inspections. Different types of inspections are clearly delineated, inspection points are clearly defined, and annual inspections as well as common inspection defects are released in a timely manner. CONCLUSION It is suggested that China should establish a perfect drug development inspection guideline system, strengthen the inspector team, and construct internal information platform.
ZANG Ke-cheng, DU Yi, SHAO Rong.
Research on FDA Bioresearch Monitoring Inspection System and Its Enlightenment to China[J]. Chinese Pharmaceutical Journal, 2022, 57(4): 321-326 https://doi.org/10.11669/cpj.2022.04.013
[1] LIU H, TIAN X J, LI H F, et al. FDA Guidance on GCP inspection regulations and administrative measures[J]. Cap Food Med, 2010, 17(2):13-14. [2] CHEN Y F, HUANG L. FDA's administration of drug clinical trials[J]. Chin J New Drugs(中国新药杂志), 2012, 21(14):1578-1582. [3] FDA. INVESTIGATIONS OPERATIONS MANUAL 2020 [EB/OL]. [2021-03-29] (2021-01-15). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/investigations-operations-manual. [4] FDA. Compliance Program Guidance Manual[EB/OL]. [2015-03-18] (2021-01-15). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-man uals/compliance-program-guidance-manual-cpgm. [5] YAO Y, ZHAO Y J, FAN X, et al. Establishment of drug registration applicant compliance management organizations in the united states and its enlightenment to China[J]. J China Pharm(中国药房), 2020, 31(12):1414-1418. [6] YANG J H, WANG Y M, FENG Y. Introduction of bioresearch monitoring program in USA Food and Drug Administration[J]. Chin J Clin Pharm(中国临床药学杂志), 2010, 26(9):711-714. [7] ZHANG S W. Establishing a legal system for food safety inspectors in China[N]. China Food Safety News(中国食品安全报), 2015-12-01(A02). [8] WANG Y W, ZHAO T, LI J, et al. Reflections and suggestions on the construction of inspectors team in China compared with the United States[J]. China Food Additives(中国食品添加剂), 2018,(11):199-202. [9] YUAN Y F, LUO J. Food inspector training model of the U.S.Food and Drug Administration and its enlightenmen t to China[J]. Meat Res(肉类研究), 2017, 31(10):63-67. [10] FDA. Good laboratory practice (Nonclinical Laboratories) [EB/OL]. [2019-03-19] (2021-01-15) https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/com pliance-program-guidance-manual-cpgm/bioresearch-monitoring-pro gram-bimo-compliance-programs. [11] FDA. Good laboratory practice program (Nonclinical Laboratories) EPA Data Audit Inspections[EB/OL]. [2003-09-30] (2021-01-15) https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-program-guidance-manual-cpgm/bioresearch-monitoring-program-bimo-compliance-programs. [12] FDA. Inspection of nonclinical laboratories conducting aimal rule-specific studies[EB/OL]. [2018-05-01] (2021-01-15) https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-program-guidance-manual-cpgm/bioresearch- monitoring-program-bimo-compliance-programs. [13] FDA. In vivo bioavailability-bioequivalence studies- clinical [EB/OL]. [2018-05-01] (2021-01-15) https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-program-guidance-manual-cpgm/bioresearch-monitoring-program-bimo-compliance-programs. [14] FDA. In vivo bioavailability-bioequivalence studies-analytical [EB/OL]. [2018-05-01] (2021-01-15) https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-program-guidance-manual-cpgm/bioresearch-monitoring-program-bimo-compliance-programs. [15] FDA. Clinical investigators and sponsor-investigators[EB/OL]. [2020-07-22] (2021-01-15) https://www.fda.gov/media/75927/download. [16] FDA. Institutional review board [EB/OL]. [2018-09-26] (2021-01-15) https://www.fda.gov/media/75909/download. [17] FDA. Sponsors, contract research organizations, and monitors[EB/OL]. [2017-04-29] (2021-01-15) https://www.fda.gov/media/75916/download. [18] FDA. Postmarketing adverse drug experience (PADE) reporting inspections[EB/OL]. [2018-09-13] (2021-01-15) https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-program-guidance-manual-cpgm/bioresearch-monitoring-program-bimo-compliance-programs. [19] FDA. Risk evaluation and mitigation strategies (REMS) reporting inspections[EB/OL]. [2020-02-01] (2021-01-15) https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-program-guidance-manual-cpgm/bioresearch-monitoring-program-bimo-compliance-programs.
PDF(1004 KB)
